Biocept, Inc. Logo

Biocept, Inc.

BIOC

(0.5)
Stock Price

0,43 USD

-132.96% ROA

-761.5% ROE

-0.02x PER

Market Cap.

0,00 USD

3996.9% DER

0% Yield

325.71% NPM

Biocept, Inc. Stock Analysis

Biocept, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Biocept, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (1.55x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

2 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

3 ROE

The stock's ROE indicates a negative return (-357.09%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-157.91%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 DER

The company has a high debt to equity ratio (3997%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Biocept, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Biocept, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

Biocept, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Biocept, Inc. Revenue
Year Revenue Growth
2011 1.052
2012 109.289 99.04%
2013 134.245 18.59%
2014 133.415 -0.62%
2015 609.909 78.13%
2016 3.223.096 81.08%
2017 5.068.663 36.41%
2018 3.250.298 -55.94%
2019 5.528.566 41.21%
2020 27.461.398 79.87%
2021 61.249.000 55.16%
2022 25.858.000 -136.87%
2023 2.356.000 -997.54%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Biocept, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 8.853.350
2012 6.562.152 -34.92%
2013 3.086.737 -112.59%
2014 4.497.790 31.37%
2015 2.857.770 -57.39%
2016 2.713.367 -5.32%
2017 3.364.747 19.36%
2018 4.468.572 24.7%
2019 4.697.022 4.86%
2020 5.220.278 10.02%
2021 4.960.000 -5.25%
2022 6.161.000 19.49%
2023 1.636.000 -276.59%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Biocept, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 2.728.442
2012 2.063.199 -32.24%
2013 2.513.136 17.9%
2014 5.201.997 51.69%
2015 5.686.398 8.52%
2016 6.560.425 13.32%
2017 7.189.529 8.75%
2018 7.074.024 -1.63%
2019 6.970.120 -1.49%
2020 9.973.082 30.11%
2021 12.614.000 20.94%
2022 16.113.000 21.72%
2023 13.976.000 -15.29%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Biocept, Inc. EBITDA
Year EBITDA Growth
2011 -12.243.801
2012 -10.569.355 -15.84%
2013 -7.677.877 -37.66%
2014 -13.873.924 44.66%
2015 -16.410.803 15.46%
2016 -18.025.037 8.96%
2017 -21.174.706 14.87%
2018 -24.258.739 12.71%
2019 -23.056.939 -5.21%
2020 -15.468.255 -49.06%
2021 -2.409.000 -542.1%
2022 -31.983.000 92.47%
2023 -22.612.000 -41.44%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Biocept, Inc. Gross Profit
Year Gross Profit Growth
2011 -16.270
2012 -1.092.405 98.51%
2013 -2.195.655 50.25%
2014 -2.037.133 -7.78%
2015 -3.986.249 48.9%
2016 -3.697.015 -7.82%
2017 -4.276.459 13.55%
2018 -6.801.437 37.12%
2019 -5.448.954 -24.82%
2020 6.124.607 188.97%
2021 23.485.000 73.92%
2022 -2.582.000 1009.57%
2023 -7.844.000 67.08%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Biocept, Inc. Net Profit
Year Net Profit Growth
2011 -13.629.286
2012 -12.259.526 -11.17%
2013 -9.233.183 -32.78%
2014 -15.866.046 41.81%
2015 -16.949.526 6.39%
2016 -18.399.322 7.88%
2017 -21.613.737 14.87%
2018 -24.571.601 12.04%
2019 -24.614.709 0.18%
2020 -17.042.320 -44.43%
2021 -2.824.000 -503.48%
2022 -32.087.000 91.2%
2023 -14.524.000 -120.92%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Biocept, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -81.612
2012 -73.410 -11.17%
2013 -55.289 -32.78%
2014 -96.744 42.85%
2015 -23.282 -315.53%
2016 -17.293 -34.64%
2017 -7.075 -144.44%
2018 -2.634 -168.56%
2019 -358 -637.82%
2020 -43 -730.23%
2021 -6 -760%
2022 -57 91.07%
2023 -14 -300%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Biocept, Inc. Free Cashflow
Year Free Cashflow Growth
2011 -11.279.746
2012 -8.615.062 -30.93%
2013 -6.203.074 -38.88%
2014 -14.999.971 58.65%
2015 -15.320.001 2.09%
2016 -16.179.123 5.31%
2017 -21.050.906 23.14%
2018 -22.500.471 6.44%
2019 -23.784.561 5.4%
2020 -20.653.914 -15.16%
2021 2.118.000 1075.16%
2022 -14.096.000 115.03%
2023 -3.183.000 -342.85%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Biocept, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -10.984.373
2012 -8.607.016 -27.62%
2013 -6.202.363 -38.77%
2014 -14.605.046 57.53%
2015 -15.154.841 3.63%
2016 -15.697.058 3.45%
2017 -19.650.726 20.12%
2018 -22.355.218 12.1%
2019 -23.049.261 3.01%
2020 -19.787.100 -16.49%
2021 3.690.000 636.24%
2022 -13.289.000 127.77%
2023 -3.086.000 -330.62%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Biocept, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 295.373
2012 8.046 -3571.05%
2013 711 -1031.65%
2014 394.925 99.82%
2015 165.160 -139.12%
2016 482.065 65.74%
2017 1.400.180 65.57%
2018 145.253 -863.96%
2019 735.300 80.25%
2020 866.814 15.17%
2021 1.572.000 44.86%
2022 807.000 -94.8%
2023 97.000 -731.96%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Biocept, Inc. Equity
Year Equity Growth
2011 -15.377.503
2012 -27.384.895 43.85%
2013 -12.456.014 -119.85%
2014 -220.569 -5547.22%
2015 3.692.735 105.97%
2016 658.661 -460.64%
2017 1.296.034 49.18%
2018 3.042.519 57.4%
2019 11.200.643 72.84%
2020 23.692.422 52.72%
2021 37.480.000 36.79%
2022 8.860.000 -323.02%
2023 290.000 -2955.17%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Biocept, Inc. Assets
Year Assets Growth
2011 2.059.489
2012 1.469.679 -40.13%
2013 1.329.719 -10.53%
2014 6.588.247 79.82%
2015 10.586.918 37.77%
2016 7.578.326 -39.7%
2017 7.378.906 -2.7%
2018 8.750.303 15.67%
2019 17.732.644 50.65%
2020 47.451.586 62.63%
2021 60.417.000 21.46%
2022 30.873.000 -95.7%
2023 22.103.000 -39.68%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Biocept, Inc. Liabilities
Year Liabilities Growth
2011 17.436.992
2012 28.854.574 39.57%
2013 13.785.733 -109.31%
2014 6.808.816 -102.47%
2015 6.894.183 1.24%
2016 6.919.665 0.37%
2017 6.082.872 -13.76%
2018 5.707.784 -6.57%
2019 6.532.001 12.62%
2020 23.759.164 72.51%
2021 22.937.000 -3.58%
2022 22.013.000 -4.2%
2023 21.813.000 -0.92%

Biocept, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
-8.71
Net Income per Share
-28.35
Price to Earning Ratio
-0.02x
Price To Sales Ratio
0x
POCF Ratio
-0.03
PFCF Ratio
0
Price to Book Ratio
1.55
EV to Sales
-0.55
EV Over EBITDA
-0.16
EV to Operating CashFlow
-0.37
EV to FreeCashFlow
-0.36
Earnings Yield
-65.19
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
13.36
Graham NetNet
-13.8

Income Statement Metrics

Net Income per Share
-28.35
Income Quality
0.46
ROE
-7.62
Return On Assets
-1.33
Return On Capital Employed
-1.85
Net Income per EBT
1
EBT Per Ebit
0.92
Ebit per Revenue
3.53
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
-0.94
Research & Developement to Revenue
-0.3
Stock Based Compensation to Revenue
-0.06
Gross Profit Margin
2.1
Operating Profit Margin
3.53
Pretax Profit Margin
3.26
Net Profit Margin
3.26

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-13.05
Free CashFlow per Share
-13.36
Capex to Operating CashFlow
0.02
Capex to Revenue
0.04
Capex to Depreciation
-0.23
Return on Invested Capital
-2.69
Return on Tangible Assets
-1.33
Days Sales Outstanding
-32.36
Days Payables Outstanding
54.17
Days of Inventory on Hand
20.35
Receivables Turnover
-11.28
Payables Turnover
6.74
Inventory Turnover
17.94
Capex per Share
-0.31

Balance Sheet

Cash per Share
6,40
Book Value per Share
0,28
Tangible Book Value per Share
0.28
Shareholders Equity per Share
0.28
Interest Debt per Share
11.32
Debt to Equity
39.97
Debt to Assets
0.52
Net Debt to EBITDA
-0.16
Current Ratio
1.81
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
39.97
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
627500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Biocept, Inc. Dividends
Year Dividends Growth

Biocept, Inc. Profile

About Biocept, Inc.

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

CEO
Mr. Darrell Taylor Esq.
Employee
50
Address
9955 Mesa Rim Road
San Diego, 92121

Biocept, Inc. Executives & BODs

Biocept, Inc. Executives & BODs
# Name Age
1 Dr. Philippe J. Marchand Ph.D.
Chief Operating Officer
70
2 Mr. Michael Terry
Senior Vice President of Corporation Devel.
70
3 Dr. Michael C. Dugan M.D.
Senior Vice President, Chief Medical Officer & Medical Director
70
4 Antonio Paternostro
Vice President of Sales
70
5 Dr. Soon Kap Hahn Ph.D.
Founder
70
6 Mr. Rob Walsh
Vice President & Controller
70
7 Dr. Veena M. Singh
Senior Medical Director
70
8 Mr. Pavel Tsinberg
Director of Technology Development
70
9 Mr. David S. Moskowitz R.Ph., MBA
Vice President of Strategy & Corporate Communications
70
10 Mr. David Karlander
Senior Vice President of Commercial Operations
70
11 Mr. Samuel D. Riccitelli
Interim Pres, Chief Executive Officer & Director
70

Biocept, Inc. Competitors